More than 1.5 million people take Invokana, according to the drug maker's website U.S. Food and Drug Administration last year issued an infection warning connected to Lo Re's death New Yorker Giacomo ...
RARITAN, N.J. and NEW ORLEANS, Nov. 3, 2017 /PRNewswire/ -- Janssen Research & Development, LLC today announced additional analyses from the landmark CANVAS clinical trial program showing INVOKANA ® ...
BOSTON, June 14, 2018 /PRNewswire/ -- Kyros Law Offices is alerting individuals that have suffered serious side effects from taking Invokana that it is investigating filing legal claims seeking ...
SAN FRANCISCO—Johnson & Johnson and its fellow SGLT2 drug makers are all working to show benefits for patients with kidney disease. But in that group, J&J can tout data its rivals don’t have. Tuesday ...
RARITAN, N.J., March 29, 2013 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved INVOKANA™ (canagliflozin) for the treatment of adults with type 2 ...
The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV ...
A drug that’s used to help control blood sugar in people with diabetes has now been shown to help prevent or slow kidney disease, which causes millions of deaths each year and requires hundreds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback